JP2012116823A - 生体組織保存溶液及びそれを用いる方法 - Google Patents
生体組織保存溶液及びそれを用いる方法 Download PDFInfo
- Publication number
- JP2012116823A JP2012116823A JP2010270886A JP2010270886A JP2012116823A JP 2012116823 A JP2012116823 A JP 2012116823A JP 2010270886 A JP2010270886 A JP 2010270886A JP 2010270886 A JP2010270886 A JP 2010270886A JP 2012116823 A JP2012116823 A JP 2012116823A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- islet
- biological tissue
- solution
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003761 preservation solution Substances 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims description 30
- 239000000243 solution Substances 0.000 claims abstract description 65
- 102000009027 Albumins Human genes 0.000 claims abstract description 19
- 108010088751 Albumins Proteins 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 14
- 210000002966 serum Anatomy 0.000 claims abstract description 13
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 9
- 150000007524 organic acids Chemical class 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 organic acid anions Chemical class 0.000 claims abstract description 7
- 230000003204 osmotic effect Effects 0.000 claims abstract description 7
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 7
- 239000011591 potassium Substances 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 238000003860 storage Methods 0.000 claims description 36
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000002542 deteriorative effect Effects 0.000 abstract description 4
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 295
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 66
- 239000008103 glucose Substances 0.000 description 66
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 55
- 239000012091 fetal bovine serum Substances 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 35
- 238000004321 preservation Methods 0.000 description 34
- 102000004877 Insulin Human genes 0.000 description 32
- 108090001061 Insulin Proteins 0.000 description 32
- 229940125396 insulin Drugs 0.000 description 32
- 230000004043 responsiveness Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 230000008859 change Effects 0.000 description 18
- 230000007423 decrease Effects 0.000 description 18
- 108091006905 Human Serum Albumin Proteins 0.000 description 15
- 102000008100 Human Serum Albumin Human genes 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 14
- 210000000496 pancreas Anatomy 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 210000004153 islets of langerhan Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000002124 endocrine Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000162 organ preservation solution Substances 0.000 description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229950000501 gabexate Drugs 0.000 description 2
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108010088854 urinastatin Proteins 0.000 description 2
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 2
- ZWGNFOFTMJGWBF-VZSHSMSCSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CC1=CN=CN1.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 ZWGNFOFTMJGWBF-VZSHSMSCSA-N 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108700027941 Celsior Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- HDTRYLNUVZCQOY-NCFXGAEVSA-N beta,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-NCFXGAEVSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
【解決手段】生体組織保存溶液は、生体組織を、非凍結状態で保存する溶液であって、アルブミンを含む。好ましくは、濃度が0.1%〜5%のアルブミン、又は濃度が5%〜30%の血清を含む。さらに好ましくは50〜240(mmol/L)のトレハロースと、10〜140(mmol/L)のナトリウムと、4〜140(mmol/L)のカリウムと、H2PO4-、HPO42-からなる群より選ばれた12〜65(mmol/L)の物質と、CL-、HCO3-、CO32-、有機酸、及び有機酸アニオンからなる群より選ばれた15〜150(mmol/L)の物質とを含み、浸透圧が270〜450(mOsm/L)で、且つpHが7〜8である生体組織保存溶液。
【選択図】なし
Description
Claims (9)
- 生体組織を、非凍結状態で保存する生体組織保存溶液であって、
アルブミンを含む
生体組織保存溶液。 - 生体組織保存溶液は、濃度が0.1%〜5%のアルブミン、又は濃度が5%〜30%の血清を含む
請求項1に記載の生体組織保存液。 - 50〜240(mmol/L)のトレハロースと、
10〜140(mmol/L)のナトリウムと、
4〜140(mmol/L)のカリウムと、
H2PO4 -、HPO4 2-からなる群より選ばれた12〜65(mmol/L)の物質と、
CL-、HCO3 -、CO3 2-、有機酸、及び有機酸アニオンからなる群より選ばれた15〜150(mmol/L)の物質とを含み、
浸透圧が270〜450(mOsm/L)で、且つpHが7〜8である
請求項1又は2に記載の生体組織保存溶液。 - さらにプロテアーゼ阻害剤を含む
請求項1〜3のいずれか1項に記載の生体組織保存溶液。 - 生体組織を、非凍結状態で保存する方法であって、
アルブミンを含む生体組織保存溶液を用いる
方法。 - 生体組織保存溶液は、濃度が0.1%〜5%のアルブミン、又は濃度が5%〜30%の血清を含む
請求項5に記載の方法。 - 生体組織保存溶液は、2〜15℃に維持される
請求項5又は6に記載の方法。 - 生体組織保存溶液は、
50〜240(mmol/L)のトレハロースと、
10〜140(mmol/L)のナトリウムと、
4〜140(mmol/L)のカリウムと、
H2PO4 -、HPO4 2-からなる群より選ばれた12〜65(mmol/L)の物質と、
CL-、HCO3 -、CO3 2-、有機酸、及び有機酸アニオンからなる群より選ばれた15〜150(mmol/L)の物質とを含み、
浸透圧が270〜450(mOsm/L)で、且つpHが7〜8である
請求項5〜7のいずれか1項に記載の方法。 - 生体組織保存溶液は、さらに、プロテアーゼ阻害剤を含む
請求項5〜8のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010270886A JP5796290B2 (ja) | 2010-12-03 | 2010-12-03 | 膵島組織保存溶液及びそれを用いる方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010270886A JP5796290B2 (ja) | 2010-12-03 | 2010-12-03 | 膵島組織保存溶液及びそれを用いる方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012116823A true JP2012116823A (ja) | 2012-06-21 |
JP2012116823A5 JP2012116823A5 (ja) | 2014-02-13 |
JP5796290B2 JP5796290B2 (ja) | 2015-10-21 |
Family
ID=46500104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010270886A Active JP5796290B2 (ja) | 2010-12-03 | 2010-12-03 | 膵島組織保存溶液及びそれを用いる方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5796290B2 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012176940A (ja) * | 2011-02-01 | 2012-09-13 | National Institute Of Advanced Industrial Science & Technology | 細胞延命効果を有するペプチドを用いた牛胚の非凍結低温保存液及び保存方法 |
WO2015182019A1 (ja) * | 2014-05-30 | 2015-12-03 | Sbiファーマ株式会社 | 臓器保存液 |
JPWO2014017267A1 (ja) * | 2012-07-25 | 2016-07-07 | 国立大学法人大阪大学 | 組織保存液および組織保存方法 |
JP2017531653A (ja) * | 2014-10-07 | 2017-10-26 | ニューテック メディカル インコーポレイテッド | 胎盤組織の低温貯蔵のための方法および組成物 |
WO2019017491A1 (ja) * | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
CN112105366A (zh) * | 2017-08-21 | 2020-12-18 | 由卫生与公众服务部部长代表的美利坚合众国 | 保护哺乳动物组织抵抗冷和其他代谢应激的组合物和方法 |
WO2021090869A1 (ja) * | 2019-11-08 | 2021-05-14 | 株式会社バイオベルデ | 幹細胞用冷蔵保存液 |
WO2021166022A1 (ja) | 2020-02-17 | 2021-08-26 | 日本ベクトン・ディッキンソン株式会社 | 試料保存用組成物 |
WO2022239556A1 (ja) * | 2021-05-11 | 2022-11-17 | 株式会社バイオベルデ | 幹細胞用冷蔵保存液及び保存方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0640801A (ja) * | 1992-07-24 | 1994-02-15 | Morishita Roussel Kk | 移植臓器用溶液 |
JPH08217601A (ja) * | 1994-05-16 | 1996-08-27 | Seitai Kagaku Kenkyusho:Kk | 生物組織保存方法および潅流液 |
JPH10511402A (ja) * | 1995-03-08 | 1998-11-04 | セロックス ラボラトリーズ,インコーポレーテッド | 凍結保存溶液 |
WO2006068226A1 (ja) * | 2004-12-22 | 2006-06-29 | Kyoto University | 膵島の分離方法 |
JP2008519830A (ja) * | 2004-11-12 | 2008-06-12 | ドールザンド・エアドライブ・ビー.ブイ. | 臓器の冷却保存および灌流のための組成物 |
JP2009513721A (ja) * | 2005-10-31 | 2009-04-02 | メディアテック,インコーポレイテッド | 単離中の膵島分離方法 |
JP2009219376A (ja) * | 2008-03-13 | 2009-10-01 | Terumo Corp | 医療用細胞の保護用液 |
WO2010075509A1 (en) * | 2008-12-26 | 2010-07-01 | Baylor Research Institute | Apparatus and method for the preservation of pancreatic tissue and islet cells for transplantation |
-
2010
- 2010-12-03 JP JP2010270886A patent/JP5796290B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0640801A (ja) * | 1992-07-24 | 1994-02-15 | Morishita Roussel Kk | 移植臓器用溶液 |
JPH08217601A (ja) * | 1994-05-16 | 1996-08-27 | Seitai Kagaku Kenkyusho:Kk | 生物組織保存方法および潅流液 |
JPH10511402A (ja) * | 1995-03-08 | 1998-11-04 | セロックス ラボラトリーズ,インコーポレーテッド | 凍結保存溶液 |
JP2008519830A (ja) * | 2004-11-12 | 2008-06-12 | ドールザンド・エアドライブ・ビー.ブイ. | 臓器の冷却保存および灌流のための組成物 |
WO2006068226A1 (ja) * | 2004-12-22 | 2006-06-29 | Kyoto University | 膵島の分離方法 |
JP2009513721A (ja) * | 2005-10-31 | 2009-04-02 | メディアテック,インコーポレイテッド | 単離中の膵島分離方法 |
JP2009219376A (ja) * | 2008-03-13 | 2009-10-01 | Terumo Corp | 医療用細胞の保護用液 |
WO2010075509A1 (en) * | 2008-12-26 | 2010-07-01 | Baylor Research Institute | Apparatus and method for the preservation of pancreatic tissue and islet cells for transplantation |
Non-Patent Citations (3)
Title |
---|
JPN6014049465; 高橋英幸ほか: 'ラット膵島移植モデルにおける移植前培養膵島に対する新鮮膵島の優位性の検証' 移植 vol.44 no.1, 20090210, p.82-90 * |
JPN6014049466; 松本逸平ほか: '短期間人膵島培養におけるfetal serum bovine(FBS)とhuman serum albumin(HSA)の比較検討' 移植 vol.40 総会臨時号, 200510, p.364 * |
JPN6014049468; 丸山通広ほか: '心停止ドナーからの臨床膵島移植' 日本臨床外科学会雑誌 vol.65 増刊号, 20040920, p.523 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012176940A (ja) * | 2011-02-01 | 2012-09-13 | National Institute Of Advanced Industrial Science & Technology | 細胞延命効果を有するペプチドを用いた牛胚の非凍結低温保存液及び保存方法 |
JPWO2014017267A1 (ja) * | 2012-07-25 | 2016-07-07 | 国立大学法人大阪大学 | 組織保存液および組織保存方法 |
WO2015182019A1 (ja) * | 2014-05-30 | 2015-12-03 | Sbiファーマ株式会社 | 臓器保存液 |
JPWO2015182019A1 (ja) * | 2014-05-30 | 2017-04-20 | Sbiファーマ株式会社 | 臓器保存液 |
JP2017531653A (ja) * | 2014-10-07 | 2017-10-26 | ニューテック メディカル インコーポレイテッド | 胎盤組織の低温貯蔵のための方法および組成物 |
JPWO2019017491A1 (ja) * | 2017-07-20 | 2020-06-25 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
WO2019017491A1 (ja) * | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
JP7248246B2 (ja) | 2017-07-20 | 2023-03-29 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
CN112105366A (zh) * | 2017-08-21 | 2020-12-18 | 由卫生与公众服务部部长代表的美利坚合众国 | 保护哺乳动物组织抵抗冷和其他代谢应激的组合物和方法 |
US11547708B2 (en) * | 2017-08-21 | 2023-01-10 | The Usa, As Represented By The Secretary, Dhhs | Compositions and methods to protect mammalian tissue against cold and other metabolic stresses |
CN112105366B (zh) * | 2017-08-21 | 2024-04-05 | 由卫生与公众服务部部长代表的美利坚合众国 | 保护哺乳动物组织抵抗冷和其他代谢应激的组合物和方法 |
WO2021090869A1 (ja) * | 2019-11-08 | 2021-05-14 | 株式会社バイオベルデ | 幹細胞用冷蔵保存液 |
WO2021166022A1 (ja) | 2020-02-17 | 2021-08-26 | 日本ベクトン・ディッキンソン株式会社 | 試料保存用組成物 |
CN115315181A (zh) * | 2020-02-17 | 2022-11-08 | 日本必帝股份有限公司 | 试样保存用组合物 |
WO2022239556A1 (ja) * | 2021-05-11 | 2022-11-17 | 株式会社バイオベルデ | 幹細胞用冷蔵保存液及び保存方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5796290B2 (ja) | 2015-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5796290B2 (ja) | 膵島組織保存溶液及びそれを用いる方法 | |
US7951590B2 (en) | Storage agent for preservation of an animal cell, tissue or organ, and preserved process of the same | |
KR950015064B1 (ko) | 기관 보존 및 저장에 적당한 조성물 | |
JP6336392B2 (ja) | 移植のための臓器又は組織の長期維持方法 | |
RU2396748C2 (ru) | Среда для хранения клеток | |
JP4931035B2 (ja) | 細胞・組織の凍結障害防止液及び凍結保存法 | |
JP6292640B2 (ja) | 臓器保存液 | |
US20150320836A1 (en) | Cryopreservation of cells inside a macro-encapsulation device | |
Daniel et al. | Extracorporeal perfusion of isolated organs of large animals-Bridging the gap between in vitro and in vivo studies | |
López-Martínez et al. | Normothermic machine perfusion systems: where do we go from here? | |
US20230087020A1 (en) | Composition for extending viable preservation and shelf-life of organs and tissues | |
Jindal et al. | Preservation and storage of pancreatic islets | |
US6361933B1 (en) | Solutions for the preservation of tissues | |
US9834756B2 (en) | Methods for increasing isolation yields of cellular products | |
US11213026B2 (en) | Solution for preserving and/or rinsing an organ to be transplanted | |
AU6141296A (en) | Compositions and methods for the preservation of living tissues | |
EP3345479B1 (en) | Preserving agent for organs or tissue and preservation method for organs or tissue | |
US6114107A (en) | Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues | |
JPH0822801B2 (ja) | 臓器保存用溶液 | |
EP4374693A1 (en) | Composition for preservation of cells, tissues or organs, comprising isolated mitochondria, and use thereof | |
Papas et al. | Pancreas and islet preservation | |
RU2731065C1 (ru) | Состав криоконсерванта для длительного хранения первичных кератиноцитов | |
KR20220050493A (ko) | 환원성 이당류를 포함하는 모유두 세포의 동결보존용 조성물 | |
Baxter et al. | Pretransplant rinse of hearts preserved with colloid-free UW solution and more effective heart preservation: studies in a rat abdominal heart transplant model | |
FR2916606A1 (fr) | Procede de rincage et de conservation d'un organe en vue de sa transplantation et solution mise en oeuvre dans ce procede |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131203 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131203 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150714 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150803 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150805 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5796290 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |